NPCE NeuroPace Inc

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001528287
AI RATING
SELL
68% Confidence

Investment Thesis

NeuroPace exhibits strong top-line growth (+25.1% YoY) with exceptional gross margins (81.8%), indicating product-market fit in the neurostimulation space. However, the company faces severe profitability and cash generation challenges: operating cash flow is deeply negative (-5.9M), net margins are -30.3%, and the high debt-to-equity ratio (4.08x) with 59M in long-term debt leaves minimal financial flexibility. With negative interest coverage and no visible path to profitability, the company's growth quality is poor.

Strengths

  • + Strong revenue growth of 25.1% YoY demonstrates market demand for products
  • + Exceptional gross margin of 81.8% indicates strong pricing power and product viability
  • + Excellent liquidity position with 5.38x current ratio and 14.8M cash provides operational runway

Risks

  • ! Deeply unprofitable with -30.3% net margin and negative operating cash flow of -5.9M
  • ! Extremely high leverage with 4.08x debt-to-equity ratio and negative interest coverage (-2.5x), limiting financial flexibility
  • ! No visible path to profitability; growth is not translating to bottom-line improvement and company remains cash flow negative

Key Metrics to Watch

Financial Metrics

Revenue
22.1M
Net Income
-6.7M
EPS (Diluted)
$-0.20
Free Cash Flow
-6.0M
Total Assets
98.9M
Cash
14.8M

Profitability Ratios

Gross Margin 81.8%
Operating Margin -25.2%
Net Margin -30.3%
ROE -46.3%
ROA -6.8%
FCF Margin -27.3%

Balance Sheet & Liquidity

Current Ratio
5.38x
Quick Ratio
4.35x
Debt/Equity
4.08x
Debt/Assets
85.4%
Interest Coverage
-2.47x
Long-term Debt
59.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-14T08:54:04.101024 | Data as of: 2026-03-31 | Powered by Claude AI